Ascendis Pharma A/S (ASND) |
|
105.55 -3.37 (-3.09%)
|
03-22 16:00 |
|
Open: |
109.33 |
Pre. Close: |
108.92 |
|
High:
|
109.745 |
Low:
|
105.41 |
|
Volume:
|
115,196 |
Market Cap:
|
6,032(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:46:13 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 133.03 One year: 140.28 |
| Support: |
Support1: 103.84 Support2: 86.4 |
| Resistance: |
Resistance1: 113.89 Resistance2: 120.1 |
| Pivot: |
109.77 |
| Moving Average: |
MA(5): 108.56 MA(20): 110.54
MA(100): 116.87  MA(250): 104.73 |
| MACD: |
MACD(12,26): -2 Signal(9): -2 |
| Stochastic oscillator: |
%K(14,3): 36.5 %D(3): 40.6 |
| RSI: |
RSI(14): 38.7 |
| 52-week: |
High: 134.52 Low: 61.57 |
| Average Vol(K): |
3-Month: 264 (K) 10-Days: 205 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASND ] has closed above bottom band by 13.7%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
111.49 - 112.04 |
112.04 - 112.48 |
|
Low:
|
105.42 - 106.16 |
106.16 - 106.76 |
|
Close:
|
107.88 - 109 |
109 - 109.91 |
|
Company Description |
|
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. |
Headline News |
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Peter Lynch - 3/19 ... - Nasdaq
Fri, 17 Mar 2023
Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This ... - Nasdaq
Mon, 06 Mar 2023
These Are The Top 10 Holdings Of David Kim - ValueWalk
Mon, 06 Mar 2023
Analysts give Ascendis Pharma A/S (NASDAQ:ASND) a "Moderate ... - Best Stocks
Mon, 20 Feb 2023
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript - Yahoo Finance
Fri, 10 Feb 2023
On Thursday, Ascendis Pharma A/S (ASND) will report earnings. - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-314 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
5.715e+007 (%) |
|
% Held by Institutions
|
5.553e+007 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
3.904e+007 |
|
EPS Est Next Qtl
|
0.01 |
|
EPS Est This Year
|
-0.15 |
|
EPS Est Next Year
|
0.14 |
|
Book Value (p.s.)
|
-11.07 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-1 |
|
Return on Equity (ttm)
|
97.8 |
|
Qtrly Rev. Growth
|
-101.7 |
|
Gross Profit (p.s.)
|
1058.83 |
|
Sales Per Share
|
-78.56 |
|
EBITDA (p.s.)
|
5.51948e+006 |
|
Qtrly Earnings Growth
|
-5.5604e+008 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
814 |
|
Price to Book value
|
-9.61 |
|
Price to Sales
|
-1.36 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
3.28e+006 |
|
Forward Dividend
|
3.16e+006 |
|
Dividend Yield
|
3086770% |
|
Dividend Pay Date
|
2023-03-16 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
